Business UpdateMay 29, 2026, 07:12 AM
Picard Medical Reports Strong Q1 2026 Revenue Growth, Emperor TAH Progress
AI Summary
Picard Medical, Inc. issued a letter to shareholders from its Chairman, Richard Fang, highlighting a transformational 2025 and a strong start to 2026. The company reported 2025 total revenue of $4.9 million and Q1 2026 revenue growth of 85% to $1.2 million, with gross profit turning positive. Significant progress was made in debt reduction and capital structure simplification, though auditors included a going-concern qualification. The letter also detailed advancements in the next-generation Emperor Total Artificial Heart and efforts to expand indications for the existing SynCardia TAH, while addressing NYSE American listing compliance concerns.
Key Highlights
- 2025 total revenue reached $4.9 million, up 12.5%, with product revenue of $4.7 million.
- Initial public offering raised $17.4 million in net equity proceeds; $9.7 million in debt financing.
- Q1 2026 revenue grew 85% to $1.2 million, with gross profit turning positive at a 24% margin.
- Repaid approximately $7.4 million of senior secured debt principal in cash in Q1 2026.
- Raised an additional $5.0 million in gross proceeds through a public offering subsequent to Q1 2026.
- Emperor TAH, a next-generation fully implantable heart, completed second-generation animal testing last week.
- Awaiting FDA decision on premarket approval supplement to expand SynCardia TAH indications.
- Received NYSE American notices regarding stockholders' equity requirements and is preparing a compliance plan by June 7, 2026.
Price Impact
More from PMI